Alvotech (ALVO) has released an update.
Alvotech has announced encouraging topline results from a patient study of AVT03, a biosimilar candidate for both Prolia and Xgeva, showing clinical similarity to the reference biologics in treatment of osteoporosis and prevention of bone-related events in cancer. With two additional studies supporting AVT03’s pharmacokinetics, safety, and tolerability, Alvotech plans to file for marketing approvals in major global markets later this year. The success of these studies marks a significant advancement in the company’s biosimilar portfolio and its commitment to providing cost-effective treatment options.
For further insights into ALVO stock, check out TipRanks’ Stock Analysis page.
